Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) directors Dr James Garner and Iain Ross have shown their faith in the company's oncology-focused drug development strategy by acquiring shares on-market.
Dr Garner, who is chief executive officer and an executive director, acquired 20,000 shares in two lots of 10,000 for total consideration of around $27,500 on August 27, 2021.
He now holds 450,000 ordinary shares in a direct interest.
Chairman and non-executive director Ross purchased 25,000 shares on August 27 for total consideration of $34,350 in a direct interest, increasing his holding to 1,025,001 ordinary shares.
Productive June quarter
Kazia has concluded a “busy and productive” June quarter as it makes great strides with the paxalisib clinical program, including the launch of two new studies.
The oncology-focused drug development company is also expecting several important read-outs targeted for the second half of the year.
All upfront payments from outbound partnering transactions in the first quarter have been received by Kazia.
On track for EVT801 study
Dr Garner said: “The second calendar quarter has been a busy and productive period for Kazia, as we bed down three substantial cross-border licensing deals.
“We have continued to make great strides with the paxalisib clinical program, with two new studies launching, and a number of important read-outs are slated for the second half.
“Meanwhile, the EVT801 program is off to a running start, and we are well on track to commence our planned Phase I study before the end of calendar 2021.”